Published in Cancer Res on November 15, 2000
Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res (2011) 3.18
History of the Baylor Charles A. Sammons Cancer Center. Proc (Bayl Univ Med Cent) (2003) 2.15
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91
Gene therapy for cancer treatment: past, present and future. Clin Med Res (2006) 1.30
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18
Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol (2005) 1.17
Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol (2009) 1.14
Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol (2009) 1.13
Cytokine determinants of viral tropism. Nat Rev Immunol (2009) 1.10
Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther (2013) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology (2006) 1.02
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets (2012) 1.01
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Viral vectors for vaccine applications. Clin Exp Vaccine Res (2013) 0.98
In situ adenovirus vaccination engages T effector cells against cancer. Vaccine (2009) 0.97
Developing novel oncolytic adenoviruses through bioselection. J Virol (2003) 0.97
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 0.95
Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol (2001) 0.94
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. Cancer Gene Ther (2006) 0.92
Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol (2002) 0.92
E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol (2004) 0.91
Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol (2012) 0.90
Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol (2009) 0.90
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther (2014) 0.89
In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci (2009) 0.89
Lessons learned from next-generation sequencing in head and neck cancer. Head Neck (2012) 0.88
Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. BMC Cancer (2012) 0.88
Progresses towards safe and efficient gene therapy vectors. Oncotarget (2015) 0.88
Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Ther (2008) 0.87
Effect of ultrasound on herpes simplex virus infection in cell culture. Virol J (2011) 0.86
Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol (2003) 0.85
Systemic therapy strategies for head-neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.84
The competitive dynamics between tumor cells, a replication-competent virus and an immune response. J Math Biol (2005) 0.83
Therapeutic targeting of tumor suppressor genes. Cancer (2014) 0.82
Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. Hum Gene Ther (2011) 0.81
Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Ther (2008) 0.81
Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors. J Transl Med (2012) 0.79
HSF1 overexpression enhances oncolytic effect of replicative adenovirus. J Transl Med (2010) 0.78
The Role of p53 and MDM2 in Head and Neck Cancer. ISRN Otolaryngol (2011) 0.78
Oncolytic viruses: do they have a role in anti-cancer therapy? Clin Med Oncol (2008) 0.78
From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Biomedicines (2016) 0.78
Gene therapy in head and neck cancer: a review. Postgrad Med J (2007) 0.77
Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol. Ann Med Health Sci Res (2014) 0.76
Activation of adenovirus early promoters and lytic phase in differentiated strata of organotypic cultures of human keratinocytes. J Virol (2003) 0.76
Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement. PLoS One (2013) 0.76
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. Biomark Cancer (2016) 0.75
An overview of gene therapy in head and neck cancer. Indian J Hum Genet (2013) 0.75
Innovations in surgical oncology at Baylor University Medical Center. Proc (Bayl Univ Med Cent) (2008) 0.75
New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J Immunother Cancer (2015) 0.75
The feasibility of gene therapy in the treatment of head and neck cancer. Head Neck Oncol (2009) 0.75
Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic Virother (2015) 0.75
[The use of p53 as a tool for human cancer therapy]. Mol Biol (Mosk) (2008) 0.75
Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes Dis (2017) 0.75
A physical map of the human genome. Nature (2001) 12.39
The sentinel node in breast cancer--a multicenter validation study. N Engl J Med (1998) 8.48
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
An essential role for Rac in Ras transformation. Nature (1995) 5.34
p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. EMBO J (1997) 5.03
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol (1998) 4.91
LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression. Infect Immun (1993) 4.90
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Building leadership capacity and future leaders in operational research in low-income countries: why and how? Int J Tuberc Lung Dis (2011) 3.40
pHG165: a pBR322 copy number derivative of pUC8 for cloning and expression. Plasmid (1986) 3.15
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther (2006) 3.09
The Union and Médecins Sans Frontières approach to operational research. Int J Tuberc Lung Dis (2011) 2.91
Applying the ICMJE authorship criteria to operational research in low-income countries: the need to engage programme managers and policy makers. Trop Med Int Health (2013) 2.78
A novel partner for the GTP-bound forms of rho and rac. FEBS Lett (1995) 2.52
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med (2000) 2.24
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
Psychiatric evaluation of a "monk" requesting castration: a patient's fable, with morals. Am J Psychiatry (1998) 2.01
Medical care costs of AIDS in Massachusetts. JAMA (1986) 1.94
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Mutant strains of Escherichia coli K12 that use D-amino acids. Proc Natl Acad Sci U S A (1971) 1.75
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 1.75
Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol (2000) 1.74
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
HIV results in the frame. Results confirmed. Nature (1995) 1.69
HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet (1995) 1.67
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol (1989) 1.67
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Histopathological and adhesion formation after incision using ultrasonic vibrating scalpel and regular scalpel in the rat. Fertil Steril (1994) 1.66
Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab (2014) 1.65
Ovarian stromal tumors containing lutein or Leydig cells (luteinized thecomas and stromal Leydig cell tumors)--a clinicopathological analysis of fifty cases. Int J Gynecol Pathol (1982) 1.63
The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J Med Screen (2005) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J (2003) 1.59
Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres. Eur Heart J (1993) 1.59
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol (1998) 1.58
Impact of waiting time on the quality of life of patients awaiting coronary artery bypass grafting. CMAJ (2001) 1.57
Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther (2008) 1.52
Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II. J Mol Biol (2000) 1.49
Practicing medicine without borders: tele-consultations and tele-mentoring for improving paediatric care in a conflict setting in Somalia? Trop Med Int Health (2012) 1.47
Should competent patients or their families be able to refuse to allow an HEC case review? Yes. HEC Forum (1995) 1.47
Tumour cell resistance to anthracyclines--a review. Cancer Chemother Pharmacol (1985) 1.45
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer (2009) 1.44
TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol (1993) 1.44
Localization of regional lymph nodes in melanomas of the head and neck. Arch Otolaryngol Head Neck Surg (1998) 1.43
Uncertainty and opposition of medical students toward assisted death practices. J Pain Symptom Manage (2001) 1.43
Use of bacterial luciferase to establish a promoter probe vehicle capable of nondestructive real-time analysis of gene expression in Bacillus spp. J Bacteriol (1987) 1.42
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther (2001) 1.42
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 1.42
Bayesian analysis of pentaquark signals from CLAS data. Phys Rev Lett (2008) 1.39
The wounds of the bull. Pharos Alpha Omega Alpha Honor Med Soc (1991) 1.39
The transcription of bacterial luminescence is regulated by sigma 32. J Biolumin Chemilumin (1989) 1.38
Malabsorption caused by coeliac disease in patients who have scleroderma. Br J Rheumatol (1995) 1.38
Use of intravenous cyclophosphamide in the prevention of corneal melt: justified or not? Rheumatology (Oxford) (2005) 1.38
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther (2001) 1.37
Measurement of two- and three-nucleon short-range correlation probabilities in nuclei. Phys Rev Lett (2006) 1.37
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther (2001) 1.36
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther (2005) 1.36
The GLBT Health Access Project: a state-funded effort to improve access to care. Am J Public Health (2001) 1.34
An ambulance referral network improves access to emergency obstetric and neonatal care in a district of rural Burundi with high maternal mortality. Trop Med Int Health (2013) 1.33
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol (1993) 1.32
Physical injecting sites among injecting drug users in Sydney, Australia. Drug Alcohol Depend (2001) 1.31
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30
Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res (2010) 1.30
An interview study of participants in the Tacoma, Washington, syringe exchange. Addiction (1993) 1.27
Pathogenesis of experimental allergic orchitis. III. T lymphocyte requirement in local adoptive transfer by peritoneal exudate cells. J Immunol (1977) 1.27
Geographical injecting locations among injecting drug users in Sydney, Australia. Addiction (2001) 1.27
Synthesis and degradation of lac mRNA in E. coli depleted of 30S ribosomal subunits. Mol Gen Genet (1979) 1.27
Conducting operational research within a non governmental organization: the example of Medecins Sans Frontieres. Int Health (2010) 1.26
Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr (2001) 1.24
Sequence and properties of operator mutations in the bio operon of Escherichia coli. Gene (1981) 1.23
Prepulse inhibition in psychiatric disorders--apart from schizophrenia. J Psychiatr Res (2013) 1.22
Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer (2013) 1.21
Treatment of flexor tenosynovitis of the hand ('trigger finger') with corticosteroids. A prospective study of the response to local injection. Arch Intern Med (1991) 1.20
Polymorphisms in the xylosyltransferase genes cause higher serum XT-I activity in patients with pseudoxanthoma elasticum (PXE) and are involved in a severe disease course. J Med Genet (2006) 1.20
Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health (1990) 1.19
Role of D-tryptophan oxidase in D-tryptophan utilization by Escherichia coli. J Bacteriol (1976) 1.19
Achieving the millennium development goal of reducing maternal mortality in rural Africa: an experience from Burundi. Trop Med Int Health (2012) 1.17
Estrogen and progesterone receptor determination in the papillary cystic neoplasm of the pancreas. With immunohistochemical and ultrastructural observations. Cancer (1987) 1.17